1. M. I. Ugwoke, R. U. Agu, N. Verbeke, R. Kinget. Nasal
mucoadhesive drug delivery: Background,
applications, trends and future perspectives,
Advanced Drug Delivery Reviews 57: 1640-1665
(2005).
2. H. P. Rang, M. M. Dale, J. M. Ritter, P. K. Moore.
Pharmacology, 5th Edition, pp. 181.
3. Martindale, Sean C. Sweetman. The Complete Drug
Reference, 33rd edition, pp. 855-856.
4. A. E. Pontiroli, A. Calderara, G. Pozza. Intranasal
drug delivery: potential advantages and limitations
from a clinical pharmacokinetic perspective, Clin.
Pharmacokinet. 17: 299–307 (1989).
5. L. Illum. Transport of drugs fromthe nasal cavity to
the central nervous system, Eur. J. Pharm. Sci. 11: 1–
18 (2000).
6. S. S. Davis, L. Illum. Absorption enhancers for nasal
drug delivery, Clin. Pharmacokinet. 42: 1107–1128
(2003).
7. T. J. Aspden, J. D. T. Mason, N. S. Jones, J. Lowe, O.
Skaugrud, L. Illum. Chitosan as a nasal delivery
system: the effect of chitosan on in vitro and in vivo
mucociliary transport rates in human turbinates
and volunteers, J. Pharm. Sci. 86: 509–513 (1997).
8. E. Gavini, A. B. Hegge, G. Rassu, V. Sanna, C. Testa, G.
Pirisino, J. Karlsen, P. Giunchedi. Nasal
administration of Carbamazepine using chitosan
microspheres: In vitro/in vivo studies, International
Journal of Pharmaceutics, 307: 9–15 (2006).
9. J. Varshosaz, H. Sadrai and R. Alinagari. Nasal
delivery of insulin using chitosan microspheres,
Microencapsulation November 2004, vol. 21, no. 7,
761–774.
10. L. Illum. Nasal drug delivery—possibilities,
problems and solutions, Journal of Controlled
Release 87: 187–198 (2003).
11. J. Elversson, A. Millqvist-Fureby, G. Alderborn, U.
Elofsson. Droplet and particle size relationship and
shell thickness of inhalable lactose particles during
spray drying, J. Pharm. Sci. 92: 900–910 (2003).
12. E. Gavini, G. Rassu, C. Muzzarelli, M. Cossu, P.
Giunchedi. Spray-dried microspheres based on
methylpyrrolidinone chitosan as new carrier for
nasal administration of metoclopramide, Eur. J.
Pharm. Sci. 68: 245–252 (2008).
13. L. J. Scott, K. L. Goa. Galantamine: a review of its use
in Alzheimer’s disease, Drugs 60 (5): 1095– 1122
(2000).
14. J. Corey-Bloom. Galantamine: a review of its use in
Alzheimer’s disease and vascular dementia, Int. J.
Clin. Pract. 57 (3): 219– 223 (2003).
15. M. W. Jann, K. L. Shirley, G. W. Small. Clinical
pharmacokinetics and pharmacodynamics of
cholinesterase inhibitors, Clin. Pharmacokinet. 41:
719–739 (2002).
16. J. G. Evans, G. Wilcock, J. Birks. Evidence-based
pharmacotherapy of Alzheimer’s disease, Int. J.
Neuropsychopharmacol. 7: 351–369 (2004).
17. A. Nordberg, A. L. Svensson. Cholinesterase
inhibitors in the treatment of Alzheimer’s disease: a
comparison of tolerability and pharmacology, Drug
Safety 20 (2):
146 (1999).
18. J. J. Sramek, E. J. Frackiewicz, N. R. Cutler. Review of
acetylcholinesterase inhibitor galantamine, Expert
Opin. Investig. Drugs 9 (10): 2393– 2402 (2000).
19. J. Poirier. Evidence that the clinical effects of
cholinesterase inhibitors are related to potency and
targeting of action, Int. J. Clin. Pract., Suppl. 127: 6 –
19 (2002).
20. B. Fulton, P. Benfield. Galanthamine, Drugs Aging 9
(1): 60– 67 (1996).
Shantanu et al., ARPB, 2012; Vol 2 (III) ISSN 2250-0774
(RESEARCH ARTICLE)
274 | P a g e w w w . a r p b . i n f o
21. A. Nordberg, A. L. Svensson. Cholinesterase
inhibitors in the treatment of Alzheimer’s disease: a
comparison of tolerability and pharmacology, Drug
Safety 20 (2): 146 (1999).
22. J. L. Cummings. Use of cholinesterase inhibitors in
clinical practice: evidence-based recommendations,
Am. J. Geriatr. Psychiatry 11 (2): 131– 145 (2003).
23. A. Kays Leonard, A. P. Sileno, C. MacEvilly, C. A.
Foerder, S. C. Quay, H. R. Costantino. Development
of a novel high-concentration galantamine
formulation suitable for intranasal delivery, J.
Pharm. Sci. 94: 1736–1746 (2005).
24. A. Kays Leonard, A. P. Sileno, G. C. Brandt, C. A.
Foerder, S. C. Quay, H. R. Costantino. In vitro
formulation optimization of intranasal galantamine
leading to enhanced bioavailability and reduced
emetic response in vivo, Int. J. Pharm. 335: 138–146
(2007).
25. D. J. V. Drooge, W. L. J. Hinrichs, H. W. Frijlink.
Anomalous dissolution behaviour of tablets
prepared from sugar glass-based solid dispersions,
J. Control. Release 97: 441–452 (2004).
26. E. Gavini, G. Rassu, C. Muzzarelli, M. Cossu, P.
Giunchedi. Spray-dried microspheres based on
methylpyrrolidinone chitosan as new carrier for
nasal administration of metoclopramide, Eur. J.
Pharm. Sci. 86: 245–252 (2008).
Thank you for copying data from http://www.arastirmax.com
